| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/30-1/150 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | CD158F; KIR2DL5; KIR2DL5.1; KIR2DL5.3 |
| WB Predicted band size | 41 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human KIR2DL5A |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于 **KIR2DL5A 抗体**的3篇代表性文献的简要总结(基于公开研究领域的典型研究方向，具体文献需通过学术数据库验证)：
---
1. **文献名称**：*Structural and functional characterization of the inhibitory receptor KIR2DL5A*
**作者**：Vilches, C., Parham, P.
**摘要**：本研究解析了KIR2DL5A的晶体结构，揭示了其与特定HLA-I类分子结合的独特位点，并证实其在NK细胞中的抑制性信号功能，为抗体设计提供结构基础。
2. **文献名称**：*KIR2DL5A polymorphisms influence HIV-1 control through both antibody-dependent and independent mechanisms*
**作者**：Alter, G., et al.
**摘要**：探讨KIR2DL5A基因多态性与HIV感染预后的关联，发现其抗体依赖的NK细胞应答可能参与病毒控制，提示其在免疫治疗中的潜在应用。
3. **文献名称**：*Expression of KIR2DL5A in tumor-infiltrating NK cells correlates with improved survival in colorectal cancer*
**作者**：Montaldo, E., et al.
**摘要**：通过临床样本分析，发现肿瘤微环境中KIR2DL5A阳性NK细胞的高浸润与结直肠癌患者生存率正相关，支持其作为预后标志物或免疫治疗靶点。
---
**注**：以上为模拟示例，实际文献需通过PubMed、Google Scholar等平台以“KIR2DL5A antibody”、“KIR2DL5A function”等关键词检索。如需具体文献，建议提供更详细的研究方向(如疾病、机制等)。
KIR2DL5A is a member of the killer cell immunoglobulin-like receptor (KIR) family, primarily expressed on natural killer (NK) cells and subsets of T lymphocytes. These receptors play a critical role in regulating NK cell activity by interacting with human leukocyte antigen (HLA) class I molecules on target cells. KIR2DL5A is classified as an inhibitory receptor due to its long cytoplasmic tail containing immunoreceptor tyrosine-based inhibitory motifs (ITIMs), which recruit phosphatases to dampen cellular activation signals. Structurally, it features two extracellular immunoglobulin-like domains that mediate ligand binding.
The ligand specificity of KIR2DL5A remains partially characterized, though some studies suggest interactions with HLA-C and HLA-F, particularly in contexts like viral infection or tumorigenesis. Its expression varies across individuals and populations, influenced by genetic polymorphisms within the highly diverse KIR gene cluster on chromosome 19. Research highlights its potential role in immune evasion by pathogens or cancers exploiting inhibitory KIR pathways to suppress NK cell-mediated cytotoxicity.
Antibodies targeting KIR2DL5A are essential tools for studying its distribution, function, and ligand interactions. They enable applications such as flow cytometry, immunohistochemistry, and functional blockade experiments to explore therapeutic strategies. For instance, blocking inhibitory KIRs (including KIR2DL5A) with monoclonal antibodies is being investigated to enhance NK cell activity against malignancies, though clinical relevance remains under exploration. Understanding KIR2DL5A's biology contributes to advancing immunotherapy and deciphering immune-related diseases.
×
